Vertex Pharmaceuticals Inc. said Monday that Canadian regulators have given their approval to Kalydeco, a drug designed to treat some patients suffering from cystic fibrosis, a rare and often fatal genetic disease. The news comes roughly 10 months after the Cambridge company received a similar approval for the drug from the Food and Drug Administration in the United States.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help